Spero TherapeuticsSPRO
13F holders, Q3 2024 (September 30)At the end of Q3 2024, 46 institutions reported holding Spero Therapeutics Inc. (SPRO) in their 13F filings, down 2 from Q2 2024. 5 opened new positions and 7 sold out. The largest holders were Anson Funds Management LP ($5.0M), Vanguard Group Inc. ($2.4M) and Acadian Asset Management LLC ($1.4M). 3 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Spero Therapeutics Inc.
- CUSIP
- 84833T103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $37K |
| Exits | 7 | $1.2M |
All 13F filers, Q2 2024 → Q3 2024: 81,520 shares bought and 1,616,163 shares sold, net −1,534,643 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 46 holders
| Anson Funds Management LP | 0.73% | No change | 3,750,450 | $5.0M |
| Vanguard Group Inc. | 0.00% | Reduce -0.4% | 1,763,620 | $2.4M |
| Acadian Asset Management LLC | 0.00% | No change | 1,071,860 | $1.4M |
| Renaissance Technologies | 0.00% | Reduce -0.1% | 974,653 | $1.3M |
| Alphabet Inc. | 0.06% | No change | 889,979 | $1.2M |
| ADAR1 Capital Management, LLC | 0.17% | Reduce -19.1% | 743,459 | $996K |
| BlackRock, Inc. | 0.00% | — | 484,820 | $650K |
| Geode Capital Management, LLC | 0.00% | Reduce -2.2% | 481,187 | $645K |
| Novo Holdings A/S | 0.03% | No change | 468,902 | $628K |
| Atlas Venture Life Science Advisors, LLC | 0.05% | Reduce -24.7% | 402,885 | $540K |
| AWM Investment Company, Inc. | 0.05% | No change | 333,400 | $447K |
| Bridgeway Capital Management, LLC | 0.01% | No change | 184,800 | $248K |
| State Street Corp. | 0.00% | No change | 130,511 | $175K |
| DAFNA Capital Management LLC | 0.04% | No change | 125,000 | $168K |
| Northern Trust Corp. | 0.00% | Reduce -0.7% | 111,497 | $149K |
| Citadel Advisors | 0.00% | Reduce -73.9% | 81,425 | $109K |
| Susquehanna International Group, LLP | 0.00% | Add +91.7% | 44,219 | $59K |
| Man Group plc | 0.00% | Reduce -47.6% | 38,481 | $52K |
| Millennium Management | 0.00% | Reduce -67.3% | 32,172 | $43K |
| Mackenzie Financial Corp. | 0.00% | Reduce -2.5% | 31,903 | $43K |
| DLK Investment Management, LLC | 0.02% | No change | 31,355 | $42K |
| Three Seasons Wealth, LLC | 0.02% | Add +100.0% | 30,000 | $40K |
| Charles Schwab Investment Management Inc. | 0.00% | No change | 28,565 | $38K |
| Shay Capital LLC | 0.01% | No change | 25,000 | $34K |
| UBS Group AG | 0.00% | Add +5195.8% | 17,529 | $23K |
| PFG Investments, LLC | 0.00% | New | 13,979 | $19K |
| Dimensional Fund Advisors LP | 0.00% | No change | 10,003 | $13K |
| National Bank of Canada | 0.00% | New | 10,000 | $13K |
| Morgan Stanley | 0.00% | No change | 6,971 | $9K |
| Russell Investments Group, Ltd. | 0.00% | No change | 6,400 | $9K |
| Bank of America Corp. | 0.00% | Add +1.7% | 5,654 | $8K |
| FMR LLC | 0.00% | Add +8.7% | 3,139 | $4K |
| CIBC Private Wealth Group LLC | 0.00% | New | 2,880 | $4K |
| WR Wealth Planners, LLC | 0.00% | No change | 2,600 | $3K |
| Cullen/Frost Bankers, Inc. | 0.00% | No change | 2,000 | $3K |
| Simplex Trading, LLC | 0.00% | New | 921 | $1K |
| Osaic Holdings, Inc. | 0.00% | No change | 295 | $395 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -2.5% | 269 | $360 |
| JPMorgan Chase & Co. | 0.00% | No change | 236 | $316 |
| Wells Fargo & Company | 0.00% | Reduce -80.0% | 200 | $268 |
| CoreCap Advisors, LLC | 0.00% | No change | 192 | $257 |
| US Bancorp \de | 0.00% | No change | 151 | $202 |
| NewEdge Advisors, LLC | 0.00% | No change | 100 | $134 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 50 | $67 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 30 | $40 |
| BNP Paribas Financial Markets | 0.00% | No change | 12 | $16 |
"% of holder's portfolio" is SPRO's weight in each manager's 13F, not the share of Spero Therapeutics Inc. the manager owns.